These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. A case of lipoatrophy with insulin detemir. Del Olmo MI; Campos V; Abellán P; Merino-Torres JF; Piñón F Diabetes Res Clin Pract; 2008 Apr; 80(1):e20-1. PubMed ID: 18281121 [TBL] [Abstract][Full Text] [Related]
4. Lipoatrophy associated with rapid-acting insulin analogues in young patients with type 1 diabetes mellitus. Szypowska A; Skórka A; Pańkowska E Pediatr Endocrinol Diabetes Metab; 2008; 14(2):117-8. PubMed ID: 18721499 [TBL] [Abstract][Full Text] [Related]
5. [Cutaneous allergic accidents caused by insulin. Current aspects apropos of 2 cases]. Plantin P; Sassolas B; Guillet MH; Tater D; Guillet G Ann Dermatol Venereol; 1988; 115(8):813-7. PubMed ID: 2974269 [TBL] [Abstract][Full Text] [Related]
6. Lipodystrophy reactions to insulin: effects of continuous insulin infusion and new insulin analogs. Radermecker RP; Piérard GE; Scheen AJ Am J Clin Dermatol; 2007; 8(1):21-8. PubMed ID: 17298103 [TBL] [Abstract][Full Text] [Related]
7. Position statement: Continuous subcutaneous insulin infusion in very young children with type 1 diabetes. Eugster EA; Francis G; Pediatrics; 2006 Oct; 118(4):e1244-9. PubMed ID: 17015512 [TBL] [Abstract][Full Text] [Related]
9. Lispro insulin-induced lipoatrophy: a new case. Al-Khenaizan S; Al Thubaiti M; Al Alwan I Pediatr Diabetes; 2007 Dec; 8(6):393-6. PubMed ID: 18036067 [TBL] [Abstract][Full Text] [Related]
13. Lipoatrophy induced by subcutaneous administration of octreotide in the treatment of acromegaly. Atmaca A; Erbas T Exp Clin Endocrinol Diabetes; 2005 Jun; 113(6):340-3. PubMed ID: 15977102 [TBL] [Abstract][Full Text] [Related]
14. [Present role of continuous subcutaneous insulin infusion (CSII) by insulin pump in the treatment of diabetes mellitus]. Pfützner A; Berger S; Spinas G Schweiz Med Wochenschr; 2000 Dec; 130(48):1854-61. PubMed ID: 11132530 [TBL] [Abstract][Full Text] [Related]
16. Safety of insulin glulisine when given by continuous subcutaneous infusion using an external pump in patients with type 1 diabetes. Hoogma RP; Schumicki D Horm Metab Res; 2006 Jun; 38(6):429-33. PubMed ID: 16823727 [TBL] [Abstract][Full Text] [Related]
17. Insulin pump therapy (continuous subcutaneous insulin infusion). White RD Prim Care; 2007 Dec; 34(4):845-71, vii. PubMed ID: 18061820 [TBL] [Abstract][Full Text] [Related]
18. Human insulin analog--induced lipoatrophy. Lopez X; Castells M; Ricker A; Velazquez EF; Mun E; Goldfine AB Diabetes Care; 2008 Mar; 31(3):442-4. PubMed ID: 18162498 [TBL] [Abstract][Full Text] [Related]
19. Skin-related complications of insulin therapy: epidemiology and emerging management strategies. Richardson T; Kerr D Am J Clin Dermatol; 2003; 4(10):661-7. PubMed ID: 14507228 [TBL] [Abstract][Full Text] [Related]
20. [Local lipohypertrophy in insulin treatment]. Herold DA; Albrecht G Hautarzt; 1993 Jan; 44(1):40-2. PubMed ID: 8436508 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]